Public health impact and economic value of booster vaccination with Pfizer-BioNTech COVID-19 vaccine, bivalent (Original and Omicron BA.4/BA.5) in the United States.

Manuela Di Fusco,Kinga Marczell,Elizabeth Thoburn,Timothy L Wiemken,Jingyan Yang,Benjamin Yarnoff

Journal of medical economics（2023）

引用 0|浏览2

暂无评分

摘要

Booster vaccination with the Pfizer-BioNTech COVID-19 Vaccine, Bivalent for the US population aged ≥5 years could generate notable public health impact and be cost-saving based on the findings of our base case analyses.

查看译文

关键词

COVID-19, SARS-CoV-2,Cost-effectiveness,I,I1,I10,I19,Pfizer-BioNTech,United States,bivalent vaccine booster,public health impact

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要